ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1640

SLICC Damage Index Is Associated with Tubulointerstitial Nephritis on Lupus Nephritis Biopsies

Cianna Leatherwood, Brigham and Women's Hospital, Boston, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Lupus and lupus nephritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

SLICC Damage Index is associated with Tubulointerstitial Nephritis on Lupus Nephritis Biopsies

Kristin D’ Silva, Paul Hoover, Gearoid McMahon, Sushrut Waikar, Helmut Rennke, Karen Costenbader

Background/Purpose: The presence of tubulointerstitial nephritis (TIN)on lupus nephritis renal biopsy has been associated with a poorer prognosis.  Clinical factors associated with this biopsy finding have not been clearly defined.    The purpose of this retrospective cohort study was to investigate clinical and laboratory characteristics associated with TIN in patients diagnosed with lupus nephritis.  We predicted low C4, elevated 24-hour urinary protein and elevated dsDNA antibodies would be associated with the presence of TIN.

Methods:   Biopsy reports of all renal biopsies performed at a single academic medical center between 1996 and 2015 showing Class II-VI lupus nephritis were reviewed.  The definition of TIN included interstitial inflammation, tubular atrophy or fibrosis, and was abstracted from the biopsy report.  All biopsies were interpreted by senior pathologists.  Demographics, clinical variables and labs at the time of biopsy were assessed by chart review. Univariable analyses and then multivariable regression models were used to identify potential factors associated with tubulointerstitial nephritis. 

Results:   165 initial lupus nephritis biopsies were identified; 119 had acute (n=5) or chronic interstitial nephritis (n= 97) or both (n=17).  The average patient age was 36 years, 85% were female, and dsDNA antibody was positive in 85%. ISSN lupus nephritis biopsy classes overall were 9% II, 25% III, 40% IV and 24% V, and class was not statistically associated with presence of TIN.  There were no statistically significant differences between groups in duration of SLE at biopsy, prior medications, age or race (Table).  In univariable analyses, presence of TIN was associated with lower hemoglobin [10.5 vs. 11 g/dL, p= 0.02], higher creatinine [1.0 vs. 0.8 mg/dL, p= 0.01], higher 24-hour urinary protein (2.62 vs. 1.4 gm, p= 0.04], and higher SLICC damage index [4 vs. 2, p= 0.0016] compared to no TIN.  Elevated SLICC damage index (DI) was associated with the presence of tubulointerstitial nephritis [OR 1.03 (95% CI 1.01, 1.05)] after controlling for age, race, sex, and 24-hour urinary protein.

Conclusion:   TIN was a common finding on lupus nephritis biopsy and not associated with ISSN Class. Several laboratory findings related to more severe renal impairment were associated with TIN, but in multivariable models only SLICC-DI remained significantly associated. This suggests that increasing SLE-related systemic damage in lupus nephritis patients is associated with increased risk of TIN.  Interestingly, SLE duration was not associated with TIN.   Further work is needed to clarify the relationship between overall SLE damage and TIN in order to identify patients at highest risk for this potentially adverse pathology.

Table.  Clinical Factors Potentially Associated with Tubulointerstitial Nephritis on Lupus Nephritis Biopsy

Tubulointerstitial nephritis (n= 119)

No Tubulointerstitial nephritis (n= 46)

p-value*

Age, mean

36 (±13)

38 (± 12)

0.55

Duration of SLE at biopsy (years), mean

6 (±8)

7 (±9)

0.58

Female, n (%)

101 (85%)

39 (85%)

0.98

Race

White, n(%)

39 (35%)

18 (39%)

0.55

Black, n(%)

41 (36%)

13 (28%)

Asian, n(%)

13 (12%)

6 (13%)

Hispanic, n(%)

19 (12%)

7 (15%)

Other

1 (1%)

2(4%)

Laboratory Values

Hemoglobin (g/dL), mean

10.5 (±2)

11 (±1.3)

0.02

Anti-dsDNA (IU/mL), median

172 [51, 488]

108 [24, 777]

0.61

Anti-RNP positive, n(%)

44 (44%)

19 (44%)

0.95

Antiphospholipid antibodies**

25 (25%)

8 (21%)

0.66

C4 (mg/dL), median

9 [6.5, 16.5]

9.5 [7, 15]

0.96

Creatinine (mg/dL), median

1.0 [0.7, 1.7]

0.8 [0.6, 1.0]

0.01

24-hr urinary protein (g/24 hr), median

2.62 [1.1, 4.5]

1.4 [0.5, 3.2]

0.04

Serum albumin, mean

3 (±0.7)

3.4 (±0.6)

0.004

Clinical factors

Prior high dose glucocorticoid***, n(%)

39 (36%)

12 (30%)

0.49

Prior immunosuppression****, n(%)

29 (27%)

6 (15%)

0.19

Prior NSAIDs, n(%)

25 (23%)

11 (28%)

0.58

SBP ≥140mmHg or DBP≥ 90mmHg, n(%)

28 (25%)

6 (14%)

0.14

SLICC-DI score*****, median

4 [1,6]

2 [1,3]

0.002

*Continuous variables evaluated with t-test or Wilcoxon and binary and categorical variables were assessed using chi-squared tests or Fisher’s exact as appropriate.

** positive vs. negative or not tested

***glucocorticoid ≥ 20 mg/day for past 30 days

**** receiving azathioprine, cyclophosphamide, mycophenolate mofetil, rituximab, cyclosporine or tacrolimus at the time of biopsy

***** Systemic Lupus Erythematosus International Collaborating Clinics damage index


Disclosure: C. Leatherwood, None;

To cite this abstract in AMA style:

Leatherwood C. SLICC Damage Index Is Associated with Tubulointerstitial Nephritis on Lupus Nephritis Biopsies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/slicc-damage-index-is-associated-with-tubulointerstitial-nephritis-on-lupus-nephritis-biopsies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/slicc-damage-index-is-associated-with-tubulointerstitial-nephritis-on-lupus-nephritis-biopsies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology